Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Pipeline Review, H1 2017

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Pipeline Review, H1 2017


  • Products Id :- GMDHC0889TDB
  • |
  • Pages: 179
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Pipeline Review, H1 2017

Summary

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 33 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Macrophage Colony Stimulating Factor 1 Receptor-Pipeline Review, H1 2017, outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 2, 5, 8, 9, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Immunology, Central Nervous System, Gastrointestinal, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Respiratory and Undisclosed which include indications Solid Tumor, Melanoma, Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ovarian Cancer, Pancreatic Cancer, Tenosynovial Giant Cell Tumor, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Breast Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Papillary Thyroid Cancer, Pigmented Villonodular Synovitis, Bladder Cancer, Colorectal Cancer, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST), Inflammation, Metastatic Colorectal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bone Metastasis, Colon Cancer, Crohn Disease (Regional Enteritis), Epithelial Ovarian Cancer, Follicular Thyroid Cancer, Lung Adenocarcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Thyroid Cancer, Acral Lentiginous Melanoma, Acute Ischemic Stroke, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Anaplastic Thyroid Cancer, Angiosarcoma, Asthma, Autoimmune Disorders, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Depression, Dysthymia, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Endometrial Cancer, Ewing Sarcoma, Fibrosarcoma, Gallbladder Cancer, Germ Cell Tumors, Gliosarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Lung Cancer, Malignant Ascites, Malignant Mesothelioma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Biliary Tract Cancer, Metastatic Liver Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neuroinflammation, Non-Small Cell Lung Carcinoma, Osteolysis, Osteosarcoma, Pain, Pancreatic Ductal Adenocarcinoma, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Pheochromocytoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Refractory Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Renal Failure, Rhabdomyosarcoma, Rheumatoid Arthritis, Salivary Gland Cancer, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Unspecified, Urticaria Pigmentosa (Mastocytosis, Mastocytoma) and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)

The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Overview

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Companies Involved in Therapeutics Development

AB Science SA

Amgen Inc

Array BioPharma Inc

BCI Pharma

Bristol-Myers Squibb Company

Cielo Therapeutics Inc

CrystalGenomics Inc

CTI BioPharma Corp

Deciphera Pharmaceuticals LLC

Eli Lilly and Company

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd

Hutchison China MediTech Ltd

Ignyta Inc

Johnson & Johnson

Nerviano Medical Sciences Srl

Novartis AG

Pfizer Inc

Plexxikon Inc

Redx Pharma Plc

SignalChem Lifesciences Corp

Syndax Pharmaceuticals Inc

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Drug Profiles

AMG-820-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-382-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLZ-945-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabiralizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCC-3014-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELB-041-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emactuzumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-2580-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMPL-012-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-28312141-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-40346527-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3022855-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMS-088-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-088-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pacritinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazopanib hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazopanib hydrochloride + pembrolizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-0360324-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexidartinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-73086-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXDX-105-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibitor CSF1R for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CSF-1 Receptor for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CSF-1R for Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FMS for Rheumatoid Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target CSF-1R-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNDX-6352-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Dormant Products

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Discontinued Products

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Product Development Milestones

Featured News & Press Releases

Jun 04, 2017: Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting

May 31, 2017: Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT (Sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery

May 18, 2017: Chi-Med Presents Clinical Data on Sulfatinib at ASCO 2017 Annual Meeting

May 18, 2017: AB Science Announces Refusal of the marketing authorisation for Masipro (masitinib)

May 18, 2017: AB Science Presents Phase 3 Data for Masitinib in Amyotrophic Lateral Sclerosis at the European Network For The Cure of ALS Annual Meeting

May 17, 2017: AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings

May 12, 2017: AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice standards

Apr 20, 2017: Five Prime to Present Clinical Data on cabiralizumab at 2017 ASCO Annual Meeting

Apr 10, 2017: Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis

Apr 07, 2017: Chi-Med Presented Pre-clinical Data for Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

Apr 03, 2017: Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting

Mar 29, 2017: AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years

Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib)

Mar 20, 2017: AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis

Mar 10, 2017: Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1)

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by AB Science SA, H1 2017

Pipeline by Amgen Inc, H1 2017

Pipeline by Array BioPharma Inc, H1 2017

Pipeline by BCI Pharma, H1 2017

Pipeline by Bristol-Myers Squibb Company, H1 2017

Pipeline by Cielo Therapeutics Inc, H1 2017

Pipeline by CrystalGenomics Inc, H1 2017

Pipeline by CTI BioPharma Corp, H1 2017

Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Pipeline by Eli Lilly and Company, H1 2017

Pipeline by Elsalys Biotech SAS, H1 2017

Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Pipeline by Hutchison China MediTech Ltd, H1 2017

Pipeline by Ignyta Inc, H1 2017

Pipeline by Johnson & Johnson, H1 2017

Pipeline by Nerviano Medical Sciences Srl, H1 2017

Pipeline by Novartis AG, H1 2017

Pipeline by Pfizer Inc, H1 2017

Pipeline by Plexxikon Inc, H1 2017

Pipeline by Redx Pharma Plc, H1 2017

Pipeline by SignalChem Lifesciences Corp, H1 2017

Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Dormant Products, H1 2017 (Contd..2), H1 2017

Dormant Products, H1 2017 (Contd..3), H1 2017

Dormant Products, H1 2017 (Contd..4), H1 2017

Discontinued Products, H1 2017

Discontinued Products, H1 2017 (Contd..1), H1 2017

Discontinued Products, H1 2017 (Contd..2), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AB Science SA

Amgen Inc

Array BioPharma Inc

BCI Pharma

Bristol-Myers Squibb Company

Cielo Therapeutics Inc

CrystalGenomics Inc

CTI BioPharma Corp

Deciphera Pharmaceuticals LLC

Eli Lilly and Company

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd

Hutchison China MediTech Ltd

Ignyta Inc

Johnson & Johnson

Nerviano Medical Sciences Srl

Novartis AG

Pfizer Inc

Plexxikon Inc

Redx Pharma Plc

SignalChem Lifesciences Corp

Syndax Pharmaceuticals Inc

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Therapeutic Products under Development, Key Players in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Therapeutics, Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Pipeline Overview, Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Pipeline, Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Pipeline Assessment

select a license
Single User License
USD 3500 INR 249830
Site License
USD 7000 INR 499660
Corporate User License
USD 10500 INR 749490

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com